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Abstract
In recent years, combinations of pharmacological treatments have become common for the treatment of
bipolar disorder type I (BP I) ; however, this practice is usually not evidence-based and rarely considers
monotherapy drug regimen (MDR) as an option in the treatment of acute phases of BP I. Therefore, we
evaluated comparative data of commonly prescribed MDRs for both manic and depressive phases of BP I.
Medline, PsycINFO, EMBASE, the Cochrane Library, the ClinicalStudyResults.org and other data sources
were searched from 1949 to March 2009 for placebo and active controlled randomized clinical trials
(RCTs). Risk ratios (RRs) for response, remission, and discontinuation rates due to adverse events (AEs),
lack of eﬃcacy, or discontinuation due to any cause, and the number needed to treat or harm (NNT or
NNH) were calculated for each medication individually and for all evaluable trials combined. The authors
included 31 RCTs in the analyses comparing aMDRwith placebo or with active treatment for acute mania,
and 9 RCTs comparing a MDR with placebo or with active treatment for bipolar depression. According to
the collected evidence, most of the MDRs when compared to placebo showed signiﬁcant response and
remission rates in acute mania. In the case of bipolar depression only quetiapine and, to a lesser extent,
olanzapine showed eﬃcacy as MDR. Overall, MDRs were well tolerated with low discontinuation rates
due to any cause or AE, although AE proﬁles diﬀered among treatments. We concluded that most MDRs
were eﬃcacious and safe in the treatment of manic episodes, but very fewMDRs have demonstrated being
eﬃcacious for bipolar depressive episodes.
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Background
A recent systematic review of 913 papers, suggested
that lithium, some anticonvulsants and second-
generation antipsychotics (SGAs) are valuable in the
treatment of acute mania (Fountoulakis & Vieta,
2008). Up until recently, ﬁrst-generation antipsychotics
(FGAs) were often the preferred choice for treatment of
acute mania, especially in European countries (Tohen
et al. 2001 ; Vestergaard, 1992) ; however, some reports
suggest that they may induce or worsen depressive
symptoms in patients with bipolar disorder (Esparon
et al. 1986 ; Zarate & Tohen, 2004). Furthermore,
patients with bipolar disorder compared to patients
with schizophrenia appear to be more susceptible
to extrapyramidal symptoms (EPS) (Cavazzoni et al.
Address for correspondence : J. M. Tamayo, M.D., BMSS.
Calle 7 # 39-197 (1619), Torre Interme´dica, Medellı´n, Colombia.
Tel. :+574-352-5749 Fax :+787-296-204
Email : tamayojm@gmail.com
International Journal of Neuropsychopharmacology (2010), 13, 813–832. Copyright f CINP 2010
doi:10.1017/S1461145709991246
REVIEW
2006; Mukherjee et al. 1986). For bipolar depressed
patients, there is uncertainty about the role of anti-
depressants as they have been associated with manic
relapse (Lewis & Winokur, 1982), lack of eﬃcacy (Post
et al. 2006 ; Sachs et al. 2007), and cycle acceleration
(Wehr & Goodwin, 1979).
Although combination drug regimens (CDRs) have
become ubiquitous in the treatment of non-refractory
BP I around the world (Baldessarini et al. 2007 ; Blanco
et al. 2002 ; Goldberg et al. 2009 ; Kupfer et al. 2002;
Levine et al. 2000 ; Wolfsperger et al. 2007), the goal of
this review was to examine the eﬃcacy and safety of
monotherapy drug regimens (MDRs). Despite treat-
ment guidelines recommending the use of mono-
therapy as a ﬁrst-line strategy (Grunze et al. 2009),
polypharmacy often occurs without evidence-based
support or sometimes without clear or adequate opti-
mization. For instance, Perlis et al. (2006) found that
diﬀerences in acute eﬃcacy in the treatment of mania
with SGAs are likely to be small, if any, between
monotherapy and add-on therapy. However, the
literature suggests that there are patients who do not
respond to acute treatment with monotherapy,
especially in bipolar depression (Blanco et al. 2002;
Goldberg et al. 2009 ; Kupfer et al. 2002). A recent meta-
analysis, however, compared co-therapy (anti-
psychotic plus mood stabilizer) with monotherapy
(mood stabilizer alone) in the treatment of bipolar
mania, and found higher response rates with co-
therapy although with decreased tolerability (Smith
et al. 2007). Cipriani et al. (2007) have suggested that the
small sample sizes and the heterogeneity of the study
designs lead to biased results favouring co-therapy.
Material and methods
Search strategy and study selection
We conducted a comprehensive literature search of all
the articles published up to March 2009 incorporating
results of searches of Medline (from 1950), PsycINFO
(from 1949), EMBASE (from 1988), the Cochrane
Library (2009 January Issue), LILACS (from 1982),
the ClinicalStudyResults.org, and two Internet search
engines : PsiTri (www.psitri.stakes.ﬁ) and Google
Scholar (scholar.google.com). A limited update litera-
ture search using Medline was performed from
15 March 2009 to 13 August 2009.
To capture articles relevant to the scope of our
review, we cross-referenced terms like ‘bipolar
disorder’, ‘manic depressive’, ‘mania’, ‘mixed’, or
‘bipolar depression’, with trial characteristics search
phrases and generic names of medications (approved
or non-approved by regulatory agencies for their use
in bipolar disorder). The full electronic search strategy
is available upon request.
We planned a priori the inclusion of studies meeting
the following criteria : randomized controlled trials
(RCTs) comparing response and/or remission rates of
a MDR with placebo or active treatment in patients
with BP I (manic/mixed or depressive episodes). We
chose discrete measures (response or remission rates)
because they are clinically meaningful outcome
measures (Lam & Kennedy, 2005). Exclusion criteria
included: use of rating scales not validated in patients
with bipolar mania, no clear deﬁnition of response or
remission criteria, or inclusion of patients who had
previously failed to respond to lithium or other mood
stabilizers. Sample size was also an eligibility criteria
to avoid weighting small studies inappropriately as
suggested by Petitti (2000) when using random-eﬀects
models. The minimum median sample was 16.5
subjects in each group as suggested by a published
empirical model (Richy et al. 2004). Additional infor-
mation required included trial duration, and medi-
cation dosage ranges. In addition, trials had to be
peer-reviewed and published.
All RCTs were identiﬁed and reviewed by two
of the authors (J.T. and G.V.). Any disagreements
were discussed in order to reach consensus. Names of
authors, institutions, or journals were not kept blind.
Evidence-based data for MDRs
We analysed the evidence supporting a therapeutic
advantage for each MDR individually and for all
evaluable trials combined vs. placebo or other active
medication if they were classiﬁed as responders (a re-
duction of at least 50% in the initial score with
any appropriate symptom rating scale) or remitters
(a predetermined minimum absolute score as rec-
ommended in the literature (Tohen et al. 2009) ; i.e.
Young Mania Rating Scale (YMRS) f12 or Mania
Rating Scale (MRS) f8 for patients with a manic/
mixed episode, or Montgomery–A˚sberg Depression
Rating Scale (MADRS) f12 or Hamilton Depression
Rating Scale (HAMD)f8 for patients with a depress-
ive episode). Rates of discontinuation due to any
cause, lack of eﬃcacy, or adverse events (AEs) were
also extracted.
Data synthesis
Studies were ﬁrst qualitatively summarized. When
more than one RCT was available for each MDR-
comparator contrast, a meta-analytical calculation was
used for each MDR. Eﬃcacy and safety dichotomous
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data were statistically combined using a random-
eﬀects model. The relative risk (RR), which is deﬁned
as the ratio of the risk of an unfavourable outcome
(non-response or non-remission) among treatment-
allocated participants to the corresponding risk of an
unfavourable outcome among those in the control
group, was estimated along with their 95% conﬁdence
intervals (CIs) using the Review Manager 5.0.21
version software (The Cochrane Collaboration, UK).
We also calculated RRs along with their 95% CIs for
discontinuation due to any cause or discontinuation
due to AEs for each MDR. Eﬀect sizes such as number
needed to treat (NNT) and number needed to harm
(NNH) were also calculated. For this purpose we
calculated risk diﬀerences (RDs), so NNT and NNH
were estimated from the RD by the formula NNT or
NNH=1/RD, with the 95% CI of NNT or NNH being
the inverse of the upper and lower limits of the 95% CI
of the RD. Only NNTs or NNHs <10 are considered
clinically meaningful (Cook & Sackett, 1995 ; Kraemer
& Kupfer, 2006).
Finally, we assessed the quality of the report on
every RCT included in this review using a scale
designed by Jadad et al. (1996). We performed x2 and I2
statistics and the visual inspection of the forest plots
derived from the x2 values to test the proportion
of total variation in study estimates that is due to
heterogeneity. This analysis contrasts the RR of the
individual trials with the pooled RR or the subgroups
of trials. An I2 of at least 50% was taken as indicator of
heterogeneity of outcome and considered inconclusive
(Egger et al. 1997, 2001 ; Higgins & Thompson, 2002 ;
Higgins et al. 2003).
Results
Included studies
We identiﬁed 101 non-duplicated RCTs, of which 40
fulﬁlled search criteria (Fig. 1). Some of the RCTs
used a three-arm design thus could be used to make
two comparisons each. In some cases, two or more
articles/references provide data for the same RCT.
The duration of most studies was 3 wk and most of
them used the YMRS for the assessment of severity of
manic symptoms. For bipolar depression, most studies
were at least 7 wk in duration and utilized either the
HAMD or the MADRS for the assessment of severity
of depressive symptoms.
Literature Search
Databases: Medline, EMBASE, PsyclNFO
  Cochrane Library, LILACS
No Limits in Language, Journal or Country
Search results combined (n = 3198)
First screen of articles on basis of title and/or abstract
Excluded (n = 3097)
Not related with bipolar disorder, long-term studies,
  combination or adjunctive therapy studies,
  sub-analyses, not pharmacological, not clinical,
  open-label studies, opinion or review papers...
Manuscript review and application of inclusion/exclusion criteria (n = 101)
Excluded (n = 61)
Sample size: 12
Absence/inappropriate evaluation of primary
  objective: 23
Not homogeneous sample: 20
Inconclusive results due to early study termination: 1
Previous no response to a mood stabilizer: 3
Combination therapy: 2
Manic/mixed episode (n = 31) Depressive episode (n = 9)
Included (n = 40)
Fig. 1. Flow of information diagram through the diﬀerent phases of the systematic review.
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MDRs for acute mixed/mania episodes
Since the ﬁrst evidence of lithium’s eﬃcacy in mania
reported by Cade (1949) a considerable number of
RCTs evaluating the eﬃcacy of lithium salts, anti-
convulsants, FGAs and SGAs used asMDRs in patients
with acute mania have been published. Many studies
that were reviewed did not meet our inclusion criteria
due to their small sample size. Other studies were ex-
cluded because they had used rating scales neither
speciﬁc nor validated for mania, had not included a
clear deﬁnition of response or remission criteria, or had
included patients that had previously not responded
to lithium or other mood stabilizers [Ballenger & Post
(1978, 1980), Berk et al. (1999), Bradwejn et al. (1990),
Brown et al. (1989), Clark et al. (1997), Cookson et al.
(1981), DelBello et al. (2005), Esparon et al. (1986),
Findling et al. (2007), Freeman et al. (1992), Garﬁnkel
et al. (1980), Garza-Trevin˜o et al. (1992), Goncalves &
Stoll (1985), Goodwin et al. (1969), Harrison & Keating
(2005), Ichim et al. (2000), Janicak et al. (1998), Johnson
et al. (1968), Kowatch et al. (2000), Kudo et al. (1987),
Lerer et al. (1987), Lyseng-Williamson & Perry (2004),
McElroy et al. (1991), Mishory et al. (2000), Moreno et al.
(2007), Okuma et al. (1979, 1990), Ortega et al. (1993),
Platman (1970), Pope et al. (1991), Post et al. (1987),
Prien et al. (1972), Segal et al. (1998), Shopsin et al.
(1975), Small et al. (1991), Spring et al. (1970), Storosum
et al. (2007), Takahashi et al. (1975), Vasudev et al.
(2000), Walton et al. (1996), and Zajecka et al. (2002)].
Four RCTs with topiramate (n=433) vs. placebo
(n=437) were presented in a combined analysis by
Kushner et al. (2006) showing no signiﬁcant eﬃcacy
diﬀerence between treatment groups. Two of those
RCTs included lithium (n=227) as an active com-
parator. Unfortunately, separate data for our primary
eﬃcacy measures were not available.
In summary, 31 RCTs in acute mania fulﬁlled our
study criteria (Table 1). Patients treated with MDR
(n=3798) had a 1.61 (95% CI 1.49–1.75, I2=26%)
higher chance of response, a 0.86 (95% CI 0.77–0.95,
I2=40%) lower risk of discontinuation due to any
cause, and a 0.55 (95% CI 0.47–0.63, I2=30%) lower
risk of discontinuation due to lack of eﬃcacy, but a
1.57 (95% CI 1.22–2.03, I2=18%) greater risk of dis-
continuation due to AEs than patients treated with
placebo (n=2299). Additional comparisons showed
that patients treated with mood stabilizers (n=1112)
had a 1.57 (95% CI 1.36–1.81, I2=33%) higher chance
of response, a 1.42 (95% CI 1.15–1.75) higher chance of
remission (I2=40%), and a 0.55 (95% CI 0.41–0.74,
I2=44%) lower risk of discontinuation due to lack of
eﬃcacy, but a 2.07 (95% CI 1.46–2.93, I2=0%) greater
risk of discontinuation due to AEs than those patients
treated with placebo (n=975). Furthermore, patients
treated with SGAs (n=2107) had a 1.59 (95% CI
1.44–1.75, I2=22%) higher chance of response, a 0.55
(95% CI 0.46–0.65, I2=16%) lower risk of discontinu-
ation due to lack of eﬃcacy, and a 0.87 (95% CI
0.79–0.95, I2=0%) lower risk of discontinuation due to
any cause, but a 1.36 (95% CI 1.03–1.79, I2=0%) higher
risk of discontinuation due to AEs than patients
treated with placebo (n=1691).
Included studies were heterogeneous with respect
to inclusion of patients with/without a rapid-cycling
course, manic/mixed states, presence/absence of
psychotic symptoms, severity of mania, rates of study
completion, and proportion of mood stabilizer-naive
subjects. Almost all the included RCTs were spon-
sored by the pharmaceutical industry, therefore, there
were not enough non-industry-sponsored studies to
explore diﬀerences related to funding source. Of
note, for tamoxifen, an experimental medication for
the treatment of acute mania, we found two small
RCTs (Yildiz et al. 2008 ; Zarate et al. 2007) including
40 patients treated with tamoxifen (dose range
40–80 mg/d) with a 7.46 (95% CI 1.90–29.32) higher
chance of response and similar risk of discontinuation
due to AEs than patients treated with placebo (n=34).
Some analyses suggested marginal diﬀerences in fa-
vour of the MDR or the comparator. In these cases we
decided to use the term ‘possibly’ to note that the
diﬀerence was not conclusive.
We considered each MDR separately :
Lithium. We found (Fig. 2 ; Tables 1 and 2) six
RCTs (Bowden et al. 1994, 2005 ; Keck et al. 2009 ; Li
et al. 2008 ; Niufan et al. 2008 ; Singh, 2008). Patients
treated with lithium (n=294) had a 1.65 (95% CI
1.23–2.21, I2=40%) higher chance of response, but
possibly a greater risk of discontinuation due to AEs
than patients treated with placebo (n=336). Inclusion
of a combined analysis with two RCTs comparing
lithium vs. placebo (Kushner et al. 2006) did not
signiﬁcantly change the RR of response (1.61, 95% CI
1.36–1.91, I2=12%). In comparison with other MDRs
(n=503), patients treated with lithium (n=467) had a
0.90 (95% CI 0.81–1.00, I2=0%) lower chance of
response.
Carbamazepine. Two RCTs with the extended release
formulation of carbamazepine (ER-CBZ) (Weisler et al.
2004, 2005) were included. Patients treated with ER-
CBZ (n=221) had a 2.02 (95% CI 1.56–2.62, I2=0%)
higher chance of response and possibly a lower risk of
discontinuation due to lack of eﬃcacy, but a greater
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Table 1. Features and results of randomized trials of monotherapy drug regimen in patients with a bipolar disorder type I
Trial (in order
of appearance
in text)
Patient inclusion
criteria
Duration
(wk)
Number
randomized
Startpexit
dosage
(mg/d) or
plasma levels
(mean)
RCT
qualitya
Sponsored
by
industry?
Responders
(%)
Remitters
(%) Signiﬁcant AE
Bowden (1994) H, 18–65 yr,
AM (SADS),
MRSo14
3 Li=36,
VAL=69,
PLA=74
Li (1950 or
1.2 mmol/l),
VAL (2000 or
93.2 mg/ml)
4 Yes Li=49,
VAL=48,
PLA=25
n.a. Li – vomiting, twitching, fever
VAL – vomiting
Bowden (2005) H,o18 yr,
AM (DSM-IV),
YMRSo20
3 Li=98,
QUE=107,
PLA=97
Li (900p
0.73 mEq/l),
QUE (400p586)
4 Yes Li=53.1,
QUE=53.3,
PLA=27.4
Li=49,
QUE=46.7,
PLA=22.1
Li – tremor, headache, ‹ TSH
QUE – dry mouth, somnolence,
‹ weight, dizziness
Keck (2009) H,>18 yr,
AM (DSM-IV-TR),
YMRSo20
3 Li=160,
ARI=155,
PLA=165
Li (900–1500)
(0.76 mEq/l),
ARI (15p23.2)
4 Yes Li=45.8,
ARI=46.8,
PLA=34.4
Li=40,
ARI=40.3,
PLA=28.2
Li – constipation, nausea, tremor
ARI – akathisia, constipation,
nausea, sedation
Niufan (2008) H,o18 yr,
AM (DSM-IV-TR),
YMRSo20
4 Li=71,
OLZ=69
Li (1110),
OLZ (17.8)
4 Yes Li=73,
OLZ=87
Li=70,
OLZ=82
Li – nausea
OLZ – ‹ weight, constipation,
somnolence
Li (2008) H, 18–65 yr,
AM (CCMD-3),
YMRSo20
4 Li=77,
QUE=78
Li (0.8 mmol/l),
QUE (648.2)
3 Yes Li=46,
QUE=60
Li=25,
QUE=40
Li – nausea, constipation,
vomiting, dizziness, diarrhoea
QUE – constipation, dizziness,
diarrhoea, ‹ ALT, ‹ AST,
palpitations, dry mouth
Singh (2008) H,o18 yr,
AM (DSM-IV),
YMRSo20
4 Li=25,
VER=25
Li (900),
VER (160p320)
3 No Li=28,
VER=32
Li=48,
VER=52
Li – constipation
VER – tremor
Weisler (2004) H,o18 yr,
AM (DSM-IV),
YMRSo20
3 ER-CBZ=101,
PLA=103
ER-CBZ
(400p756.44
or 8.9 mg/ml)
4 Yes ER-CBZ=41.5,
PLA=22.4
n.a. ER-CBZ – dizziness, nausea,
somnolence, vomiting,
dyspepsia, dry mouth, pruritus,
speech disorder
Weisler (2005) H,o18 yr,
AM (DSM-IV),
YMRSo20
3 ER-CBZ=120,
PLA=115
ER-CBZ
(400p642.6)
4 Yes ER-CBZ=61,
PLA=29
n.a. ER-CBZ – dizziness, somnolence,
nausea, ataxia, vomiting,
blurred vision
Wagner (2006) O, 7–18 yr,
AM (DSM-IV),
YMRSo20
7 OXC=59,
PLA=57
OXC (300p1515) 4 Yes OXC=42,
PLA=26
n.a. OXC – dizziness, nausea,
somnolence, diplopia,
fatigue, rash
Bowden (2006) H, 18–65 yr,
AM (DSM-IV),
MRSo18
3 VAL=192,
PLA=185
VAL (3057 or
95.9 mg/ml)
4 Yes VAL=48,
PLA=34
VAL=48,
PLA=35
VAL – somnolence, dizziness,
GI complaints
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Table 1 (cont.)
Trial (in order
of appearance
in text)
Patient inclusion
criteria
Duration
(wk)
Number
randomized
Startpexit
dosage
(mg/d) or
plasma levels
(mean)
RCT
qualitya
Sponsored
by
industry?
Responders
(%)
Remitters
(%) Signiﬁcant AE
Tohen (2008) O+H, 18–65 yr,
AM (DSM-IV-TR),
YMRS=20–30
3 VAL=201,
OLZ=215,
PLA=105
VAL (848.4),
OLZ (11.4)
4 Yes VAL=40.3,
OLZ=40.8,
PLA=31.3
VAL=40.3,
OLZ=42.8,
PLA=35.4
VAL – nausea, insomnia,
› platelets, › leukocytes,
‹ appetite OLZ – ‹ weight,
‹ TGl, ‹ Glu, ‹ Chol,
‹ prolactin, somnolence
DelBello (2006) H, 12–18 yr,
AM (DSM-IV-TR),
YMRSo20
4 VAL=25,
QUE=25
VAL (20 mg/
kg.dp101 mg/ml),
QUE (100p412),
3 No n.a. VAL=60,
QUE=28
VAL – ›platelets
QUE – ‹ ALT
McElroy (1996) H, 18–65 yr,
AM (DSM-III-R),
psychotic
1 VAL=21,
HAL=15
VAL (20 mg/
kg.dp1625.8),
HAL (0.2 mg/
kg.dp15.5)
3 VAL=47.6,
HAL=33.3
n.a. HAL – EPS
Tohen (2002) H, 18–65 yr,
AM (DSM-IV),
YMRSo20
3 VAL=123,
OLZ=125
VAL (750p1554.1
or 83.9 mg/ml),
OLZ (15p16.2),
4 Yes VAL=42.3,
OLZ=54.4
VAL=34.1,
OLZ=47.2
VAL – nausea, › platelets
OLZ – somnolence, dry mouth,
‹ appetite, tremor,
speech disorder, rigidity, ‹ALT
Wagner (2009) O, 10–17 yr, AM
(DSM-IV-TR),
YMRSo20
4 VAL=76,
PLA=74
VAL (15 mg/
kg.dp1286)
4 Yes VAL=24,
PLA=23
VAL=16,
PLA=19
VAL – nausea, abdominal pain,
‹ weight, › platelets,
‹ serum ammonia
Kushner (2006) –
PDMD-004, –005,
–006, –008
H,o16 yr,
AM (DSM-IV),
YMRSo20
3 TOP=433,
PLA=427
TOP (50p400) n.a. Yes TOP=27,
PLA=28
TOP=24,
PLA=23
TOP – headache, paresthesia,
› appetite Li – diarrhoea, tremor
McIntyre (2005) o18 yr,
AM (DSM-IV),
YMRSo20
3 HAL=99,
QUE=101,
PLA=100
HAL (5.2),
QUE (400p559)
4 Yes HAL=56.1,
QUE=42.6,
PLA=35
HAL=36.7,
QUE=27.7,
PLA=24
HAL – tremor, akathisia, EPS
QUE – somnolence
Smulevich (2005) o18 yr,
AM (DSM-IV),
MRSo20
3 HAL=144,
RIS=154,
PLA=140
HAL (8.0),
RIS (4.2)
4 Yes HAL=47,
RIS=48,
PLA=33
n.a. RIS – EPS, hyperkinesia,
somnolence, hypertonia,
‹ prolactinb HAL – EPS,
hyperkinesia,
tremor, hypertonia
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Vieta (2008) H,o18 yr,
overweight,
AM (DSM-IV-TR),
MRSo14
3 HAL=171,
ZIP=178,
PLA=88
HAL (8p16),
ZIP (80p116.2)
4 Yes HAL=54.7,
ZIP=36.9,
PLA=20.5
HAL=31.9,
ZIP=22.7
ZIP – EPS, akathisia, dyspepsia,
‹ weight, headache
HAL – EPS, akathisia, somnolence,
dystonia, dizziness, hypotonia,
anxiety, tremor, depression,
hypokinesia
Young (2009) o18 yr,
AM (DSM-IV-TR),
YMRSo20
3 HAL=165,
ARI=167,
PLA=153
HAL (5p8.5),
ARI (15p23.6)
4 Yes HAL=49.7,
ARI=47,
PLA=38.2
HAL=45.3,
ARI=44,
PLA=36.8
HAL – EPS, akathisia,
muscle rigidity, ‹ prolactin
ARI – insomnia, akathisia, EPS
Tohen, 2003 H & OP,o18 yr,
AM (DSM-IV),
YMRSo20
6 HAL=219,
OLZ=234
HAL (10p7.1),
OLZ (15p15)
4 Yes HAL=62,
OLZ=55
HAL=46.1,
OLZ=52.1
OLZ – somnolence,‹ weight,
dizziness, fever
HAL – salivation, EPS, akathisia,
tremor, hypertonia,
dystonia, dyskinesia
Vieta (2005) o18 yr,
AM (DSM-IV),
YMRSo20
3 HAL=172,
ARI=175
HAL (10p11.6),
ARI (10p22.6)
4 Yes HAL=42.6,
ARI=50.9
HAL=31,
ARI=35
ARI – insomnia
HAL – EPS, akathisia, ‹ prolactin
Keck (2003a) H,o18 yr,
AM (DSM-IV),
YMRSo20
3 ARI=123,
PLA=120
ARI (30p27.9) 4 Yes ARI=40,
PLA=19
n.a. ARI – nausea, dyspepsia, vomiting,
constipation, somnolence, EPS,
akathisia
Sachs (2006) o18 yr,
AM (DSM-IV-TR),
YMRSo20
3 ARI=137,
PLA=135
ARI (30p27.7) 4 Yes ARI=53,
PLA=32
n.a. ARI – constipation, dyspepsia,
nausea, somnolence, akathisia
Tohen (1999) H, 18–65 yr,
AM (DSM-IV),
YMRSo20
3 OLZ=70,
PLA=69
OLZ (10p14.9) 4 Yes OLZ=49,
PLA=24
n.a. OLZ – somnolence, dry mouth,
dizziness, ‹weight
Tohen (2000) H, 18–70 yr,
AM (DSM-IV),
YMRSo20
4 OLZ=54,
PLA=56
OLZ (15p16.4) 4 Yes OLZ=64.8,
PLA=42.9
OLZ=61.1,
PLA=35.7
OLZ – somnolence
Tohen (2007) H, 13–17 yr,
AM (DSM-IV-TR),
YMRSo20
3 OLZ=107,
PLA=54
OLZ (2.5p10.7) 4 Yes OLZ=48.6,
PLA=22.2
OLZ=35.2,
PLA=11.1
OLZ – somnolence, ‹ weight,
sedation
Perlis (2006) H, 18–70 yr,
AM (DSM-IV-TR),
YMRSo20
3 OLZ=165,
RIS=164
OLZ (14.7),
RIS (3.9)
4 Yes OLZ=62,
RIS=59.5
OLZ=38.5,
RIS=28.5
OLZ – dry mouth, ‹ weight
RIS – anxiety, joint stiﬀness,
‹ prolactin
Hirschfeld
(2004)
o18 yr,
AM (DSM-IV),
YMRSo20
3 RIS=125,
PLA=134
RIS (4.1) 5 Yes RIS=43,
PLA=24
RIS=38,
PLA=20
RIS – somnolence, EPS,
hyperkinesia, dyspepsia,
nausea, ‹ prolactin, ‹ weight
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Table 1 (cont.)
Trial (in order
of appearance
in text)
Patient inclusion
criteria
Duration
(wk)
Number
randomized
Startpexit
dosage
(mg/d) or
plasma levels
(mean)
RCT
qualitya
Sponsored
by
industry?
Responders
(%)
Remitters
(%) Signiﬁcant AE
Khana (2005) ;
Gopal (2005)
o18 yr,
AM (DSM-IV),
YMRSo20
(mean score
V1=37)
3 RIS=146,
PLA=144
RIS (5.6) 4 Yes RIS=73,
PLA=36
RIS=42,
PLA=13
RIS – EPS, tremor, dystonia,
‹ prolactinc
Keck (2003b) H,o18 yr,
AM (DSM-IV),
MRSo14
3 ZIP=131,
PLA=66
ZIP (80p130) 3 Yes ZIP=50,
PLA=35
n.a. ZIP – somnolence, headache,
dizziness, hypertonia, akathisiad
Potkin (2005) H,o18 yr,
AM (DSM-IV),
MRSo14
3 ZIP=137,
PLA=65
ZIP (80p112) 4 Yes ZIP=46,
PLA=29
n.a. ZIP – somnolence,
EPS, dizziness, tremord
Calabrese (1999) o18 yr, MDE
(DSM-IV),
HAMDo18
7 LAM50=64,
LAM200=63,
PLA=65
LAM50(25p50),
LAM200 (25p200)
4 Yes LAM50=45,
LAM200=51,
PLA=37
n.a. LAM200 – headache
Calabrese (2008) ;
Geddes (2009) –
SCA40910
o18 yr, MDE
(DSM-IV),
HAMDo18
8 LAM200=133,
PLA=124
LAM200 (25p200) n.a. Yes LAM200=41.4,
PLA=37.9
n.a. LAM200 – xerostomia
Calabrese (2008) ;
Geddes (2009) –
SCA30924
o18 yr,
MDE (DSM-IV),
HAMDo18
8 LAM200=131,
PLA=128
LAM200 (25p200) n.a. Yes LAM200=45.5,
PLA=40
LAM200=26.8,
PLA=30
LAM200 – diarrhoea, somnolence,
dizziness, rash
Thase (2008) –
CN138-096
O, 18–65 yr, MDE
(DSM-IV-TR),
HAMDo18
8 ARI=186,
PLA=188
ARI (10p30) 4 Yes ARI=43.2,
PLA=39
ARI=30.2,
PLA=27.8
ARI – akathisia, insomnia, nausea,
fatigue, restlessness, dry mouth,
vomiting, ‹ appetite, back pain
Thase (2008) –
CN138-146
O, 18–65 yr,
MDE (DSM-IV-TR),
HAMDo18
8 ARI=187,
PLA=188
ARI (10p30) 4 Yes ARI=44.6,
PLA=44.3
ARI=25.7,
PLA=29
ARI – akathisia, nausea, fatigue,
restlessness, anxiety, vomiting,
‹ appetite
Tohen (2003b) –
3077a S1
o18 yr, MDE
(DSM-IV),
MADRSo20
8 OLZ=181,
PLA=182
OLZ (9.7) 4 Yes OLZ=43.6,
PLA=37.6
OLZ=55,
PLA=46.3
OLZ – ‹appetite, ‹ weight,
‹ Chol, asthenia,
dry mouth, somnolence
Tohen (2003b) –
3077a S2
o18 yr,
MDE (DSM-IV),
MADRSo20
8 OLZ=169,
PLA=174
OLZ (9.7) 4 Yes OLZ=53.3,
PLA=34.7
OLZ=57,
PLA=44
Combined data on Tohen
(2003) above
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risk of discontinuation due to AEs than patients
treated with placebo (n=218). The NNH analysis
suggested that four patients treated with carbamaz-
epine instead of placebo are needed to observe an
additional AE.
Oxcarbazepine. One 7-wk RCT with the use of
oxcarbazepine in children and adolescents was
included (Wagner et al. 2006). Although it was
reported that oxcarbazepine did not signiﬁcantly
improve YMRS scores at endpoint compared with
placebo, we found that patients treated with
oxcarbazepine (n=59) had a 1.56 (95% CI 1.13–2.16)
higher chance of response, although a greater risk
of discontinuation due to AEs than patients treated
with placebo (n=57). Nine patients are needed to
observe an additional AE if patients are treated with
oxcarbazepine instead of placebo.
Valproate/divalproex. Seven RCTs were included
(Bowden et al. 1994, 2006 ; DelBello et al. 2006 ;
McElroy et al. 1996 ; Tohen et al. 2002, 2008 ; Wagner
et al. 2009). Patients treatedwith valproate (n=555) had
a 1.39 (95% CI 1.16–1.65, I2=0%) higher chance
of response, a 1.27 (95% CI 1.05–1.54) higher chance
of remission (I2=72%) and a lower risk of
discontinuation due to lack of eﬃcacy, but had a
greater risk of discontinuation due toAEs than patients
treated with placebo (n=457). Nine patients are
needed to observe an additional AE if patients are
treated with valproate instead of placebo. In
comparison with other MDRs (n=416), patients
treated with valproate (n=439) had a similar chance
of response, but a lower risk of discontinuation due to
AEs. The exclusion of RCTs in children and adolescents
(DelBello et al. 2006 ; Wagner et al. 2009) does not
change the RR for either response vs. placebo or
remission vs. other MDRs.
Haloperidol. Seven RCTs with haloperidol were
included (McElroy et al. 1996 ; McIntyre et al. 2005 ;
Smulevich et al. 2005; Tohen et al. 2003a ; Vieta et al.
2005, 2008 ; Young et al. 2009). Patients treated with
haloperidol (n=579) had a 1.31 (95% CI 1.04–1.65,
I2=0%) higher chance of remission and a 1.63 (95% CI
1.25–2.12) higher chance of response (I2=64%) than
patients treated with placebo (n=481). Although
patients treated with haloperidol showed no in-
creased risk of discontinuation for any cause or AE,
a study showed that only two patients treated with
haloperidol instead of placebo are needed to observe
an additional AE. In comparison with other MDRs
(n=985), patients treated with haloperidol (n=1030)M
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showed a similar chance of response (I2=62%) or
remission (I2=51%). The NNT analyses indicated
that ﬁve patients treated with haloperidol instead
of another MDR are needed to observe an additional
AE.
Aripiprazole. Five RCTs were included (Keck et al.
2003a, 2009 ; Sachs et al. 2006; Vieta et al. 2005 ; Young
et al. 2009). Patients treated with aripiprazole
(n=582) had a 1.50 (95% CI 1.22–1.84, I2=44%)
higher chance of response and a 1.28 (95% CI
1.05–1.57, I2=0%) higher chance of remission than
patients treated with placebo (n=573). Eight patients
treated with aripiprazole instead of placebo are
needed to observe an additional AE. In comparison
with other MDRs (n=497), patients treated with
aripiprazole (n=497) had a similar chance of
response and remission.
Study or subgroup
(1st-named author)
MDR
Events Total
Placebo
Events Total
Weight
(%)
Risk ratio
M-H, random, 95% Cl 
Risk ratio
M-H, random, 95% Cl 
Lithium
   Bowden, 1994 
   Bowden, 2005 
   Keck, 2009 
   Total (95% CI) I 2 = 40%
Valproate 
   Bowden, 1994 
   Bowden, 2006 
   Tohen, 2008 
   Wagner, 2009 
   Total (95% CI) I 2 = 0%
Oxcarbazepine 
   Wagner, 2006
ER-CBZ 
   Weisler, 2004 
   Weisler, 2005 
   Total (95% CI) I 2 = 0%
Haloperidol 
   Mclntyre, 2005 
   Smulevich, 2005 
   Vieta, 2008 
   Young, 2009 
   Total (95% CI) I 2 = 64% 
Aripiprazole 
   Keck, 2003a 
   Keck, 2009 
   Sachs, 2006 
   Young, 2009 
   Total (95% CI) I 2 = 44%
Olanzapine
   Tohen, 1999 
   Tohen, 2000 
   Tohen, 2007 
   Tohen, 2008 
   Total (95% CI) I 2 = 27%
Quetiapine 
   Bowden, 2005 
   Mclntyre, 2005 
   Total (95% CI) I 2 = 68%
Risperidone 
   Hirschfeld, 2004 
   Khanna, 2005 
   Smulevich, 2005 
   Total (95% CI) I 2 = 33%
Ziprasidone
   Keck, 2003b 
   Potkin, 2005 
   Vieta, 2008 
   Total (95% CI) I 2 = 0%
Total (95% CI)
Heterogeneity: τ 2 = 0.01; χ 2 = 28.23, d.f. = 21 (p = 0.13); I2 = 26%
Test for overall effect: Z = 11. 29 (p < 0.00001)
25.2
26.6
19.2
29.0
100.0
16.1
28.5
26.0
29.4
100.0
100.0
40.8
31.9
27.2
100.0
24.0
42.5
33.5
100.0
49.3
50.7
100.0
19.4
30.7
16.9
33.0
100.0
100.0
36.1
63.9
100.0
14.7
50.1
26.0
9.2
100.0
18
52
73
143
33
92
75
18
218
42
56
68
94
82
300
99
144
171
165
579
49
73
73
78
273
123
155
137
167
582
34
35
52
82
215
57
43
100
54
107
74
235
66
63
66
195
1824 3798
131
137
178
446
125
146
154
425
107
101
208
70
54
107
215
446
59
42
73
115
101
120
221
69
192
201
76
538
36
98
160
294
35
46
18
58
157
100
140
88
153
481
23
57
43
58
181
120
165
135
153
573
697 2299
23
19
18
60
66
65
88
219
32
52
46
130
134
144
140
418
27
35
62
97
100
197
16
24
12
31
83
69
56
54
105
284
26 57
23
33
56
103
115
218
19
63
31
17
130
74
185
105
74
438
19
26
57
103
74
97
165
336
22.8
32.7
45.7
100.0
1.95 (1.17–3.23)
1.91 (1.32–2.76)
1.32 (1.01–1.73)
1.62 (1.23–2.13)
1.86 (1.18–2.95)
1.41 (1.10–1.80)
1.26 (0.89–1.79)
1.03 (0.58–1.84)
1.39 (1.16–1.65)
1.56 (1.13–2.16)
1.62 (1.18–2.22)
1.44 (1.07–1.93)
2.69 (1.74–4.15)
1.31 (1.02–1.69)
1.63 (1.25–2.12)
1.86 (1.21–2.86)
2.12 (1.54–2.92)
2.02 (1.56–2.62)
2.08 (1.36–3.18)
1.36 (1.04–1.78)
1.67 (1.25–2.24)
1.23 (0.95–1.60)
1.49 (1.22–1.83)
2.09 (1.28–3.43)
1.51 (1.05–2.17)
2.19 (1.28–3.74)
1.29 (0.92–1.82)
1.63 (1.28–2.08)
1.91 (1.33–2.76)
1.22 (0.86–1.73)
1.52 (0.97–2.37)
1.81 (1.26–2.60)
2.03 (1.60–2.58)
1.46 (1.10–1.95)
1.77 (1.44–2.17)
1.45 (1.00–2.10)
1.57 (1.03–2.39)
1.81 (1.15–2.86)
1.58 (1.25–2.00)
1.61 (1.49–1.75)
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours MDR
Fig. 2. Random risk ratios and 95% conﬁdence intervals (CIs) for response rates with a monotherapy drug regimen (MDR) vs.
placebo in the treatment of acute manic episodes. Response is deﬁned as a reductiono50% in the baseline total score in the
primary eﬃcacy measure after 3–6 wk of treatment. ER-CBZ, Extended-release carbamazepine capsules ; M-H,
Mantel–Haenszel.
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Table 2. Secondary eﬃcacy and safety measures of randomized trials using monotherapeutic drug regimen in patients with a bipolar disorder type I
MDR and comparator
NNT response
(95% CI)
NNT remission
(95% CI) NNH (95% CI)
Relative risk of
discontinuation due
to any cause (95% CI) [I2]
Relative risk of
discontinuation due
to AE (95% CI) [I2]
Relative risk of
discontinuation due to
lack of eﬃcacy (95% CI) [I2]
Manic/mixed episode
Li PLA 5 (3–8) 6 (3–8) 26 (x27 to 79) 0.78 (0.52–1.18) [84%] 1.74 (1.00–3.02) [0%] 0.53 (0.29–0.98) [67%]
MDR x23 (x56 to 11) x23 (x59 to 13) x11 (x18 tox3) 1.25 (0.91–1.72) [61%] 1.03 (0.65–1.64) [1%] 1.36 (0.69–2.68) [55%]
EC-CBZ PLA 4 (3–5) n.a. 4 (3–5) 0.85 (0.69–1.03) [0%] 1.97 (1.04–3.74) [0%] 0.44 (0.20–1.00) [65%]
OXC PLA 4 (1–7) n.a. 9 (x2 to 20) 0.84 (0.52–1.35)a 5.31 (1.23–22.93)a 0.41 (0.17–1.00)*
VAL PLA 9 (4–14) 12 (3–22) 9 (4–14) 0.89 (0.73–1.08) [26%] 2.42 (1.28–4.56) [0%] 0.63 (0.43–0.92) [27%]
MDR x31 (x99 to 36) x12 (x22 tox2) x132 (x1 to1) 0.93 (0.81–1.07) [0%] 0.56 (0.32–0.98) [0%] 1.01 (0.66–1.56) [0%]
HAL PLA 5 (4–7) 10 (2–17) 2 (2–3)a 0.82 (0.67–1.01) [18%] 1.19 (0.40–3.53) [79%] 0.52 (0.22–1.26) [77%]
MDR 22 (1–44) 118 (x531 to 767) 5 (4–7) 1.15 (0.95–1.40) [62%] 1.55 (0.96–2.48) [67%] 0.72 (0.42–1.22) [69%]
ARI PLA 7 (4–9) 10 (2–19) 8 (3–12) 0.98 (0.83–1.17) [0%] 1.21 (0.84–1.75) [7%] 0.67 (0.33–1.38) [72%]
MDR 41 (x65 to 148) 124 (x1 to1) x3 (x4 tox2) 0.86 (0.65–1.14) [76%] 0.86 (0.33–2.24) [89%] 1.46 (0.72–2.95) [68%]
OLZ PLA 6 (3–9) 7 (3–12) 6 (3–10) 0.68 (0.53–0.87) [34%] 1.93 (0.48–7.72) [28%] 0.57 (0.42–0.77) [0%]
MDR 57 (x102 to 215) 13 (5–22) 15 (x4 to 35) 0.86 (0.69–1.07) [62%] 1.01 (0.59–1.72) [44%] 0.93 (0.66–1.31) [0%]
QUE PLA 6 (3–9) 7 (3–11) n.a. 0.66 (0.39–1.10) [78%] 1.59 (0.48–5.25)a 0.43 (0.21–0.87)*
MDR x88 (x724 to 548) 32 (x49 to 114) 11 (x5 to 26)a 0.76 (0.38–1.50) [59%] 0.62 (0.31–1.25) [0%] 0.88 (0.36–2.17) [37%]
RIS PLA 4 (3–5) 4 (3–6) n.a. 0.66 (0.41–1.08) [67%] 1.18 (0.62– 2.27) [0%] 0.44 (0.29–0.65) [0%]
MDR x108 (x1013 to 797) x10 (x20 to 1) n.a. 1.43 (1.04–1.97) [0%] 1.51 (0.77–2.99) [0%] 1.27 (0.53–3.02) [0%]
ZIP PLA 6 (3–9) n.a. 6 (3–8) 0.84 (0.73–0.96) [0%] 2.40 (1.01–5.68) [0%] 0.56 (0.44–0.72) [0%]
MDR x6 (x9 tox2)a x10 (x20 tox1) x6 (x10 tox3)a 1.07 (0.89–1.29)a 0.45 (0.27–0.78)a 2.24 (1.41–3.57)a
MS PLA 6 (5–8) 9 (5–12) 11 (6–16) 0.84 (0.71–0.99) [65%] 2.07 (1.46–2.93) [0%] 0.55 (0.41–0.74) [44%]
SGA PLA 6 (5–7) 8 (6 :10) 7 (5–10) 0.87 (0.79–0.95) [0%] 1.36 (1.03–1.79) [0%] 0.55 (0.46–0.65) [16%]
MDR PLA 6 (5–7) 7 (5–8) 9 (6–12) 0.81 (0.73–0.90) [51%] 1.57 (1.22–2.03) [18%] 0.55 (0.47–0.63) [30%]
Bipolar depressive episode
LAM PLA 16 (x4 to 36) x34 (x159 to 91)a 511 (x1 to1) 1.35 (0.85–2.14) [0%] 0.79 (0.38–1.62) [0%] 1.10 (0.80–1.51) [51%]
ARI PLA 45 (x100 to 190) x174 (x1 to1) 14 (x2 to 29)* 2.10 (1.32–3.35) [0%] 0.45 (0.23–0.88) [0%] 1.35 (1.13–1.63) [0%]
OLZ PLA 8 (3–14) 9 (2–16) n.a. 0.72 (0.59–0.88) [63%] 1.82 (1.06–3.13)b 0.62 (0.48–0.80) [0%]
QUE PLA 4 (3–6) 4 (3–6)** n.a. 1.01 (0.83–1.22)a 1.95 (1.15–3.30)a 0.18 (0.09–0.37)a
SGA PLA 8 (5–10) 9 (6–13) n.a. 0.99 (0.73–1.32) [90%] 1.97 (1.47–2.64) [0%] 0.46 (0.29–0.71) [64%]
MDR PLA 9 (6–12) 10 (6–15) n.a. 1.02 (0.81–1.28) [86%] 1.77 (1.38–2.26) [0%] 0.51 (0.36–0.73) [46%]
ARI, Aripiprazole ; CBZ, carbamazepine ; CI, conﬁdence interval ; ER-CBZ, extended-release carbamazepine capsules ; Li, lithium; LAM, lamotrigine ; MDR, monotherapy drug
regime; MS, mood stabilizers ; n.a., non-available ; NNH, number needed to harm; NNT, number needed to treat ; OLZ, olanzapine ; OXC, oxcarbazepine ; PLA, placebo ; QUE,
quetiapine ; RIS, risperidone ; SGA, second-generation antipsychotics ; VAL, valproate/divalproex ; VER, verapamil ; ZIP, ziprasidone.
a Based on one RCT.
b Based on combined data from two RCTs.
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Olanzapine. Eight RCTs were included (Niufan et al.
2008 ; Perlis et al. 2006 ; Tohen et al. 1999, 2000, 2002,
2003a, 2007, 2008). Patients treated with olanzapine
(n=446) had a 1.62 (95% CI 1.27–2.08, I2=27%) higher
chance of response, a 1.68 (95% CI 1.06–2.64) higher
chance of remission (I2=62%), and had a lower risk of
discontinuation due to any cause or lack of eﬃcacy
than patients treated with placebo (n=284). Six
patients treated with olanzapine instead of placebo
are needed to observe an additional AE. In comparison
with other MDRs (n=778), patients treated with
olanzapine (n=808) had a 1.17 (95% CI 1.06–1.30,
I2=0%) higher chance of remission, and a similar
chance of response.
Quetiapine. Four RCTs were included (Bowden et al.
2005 ; DelBello et al. 2006 ; Li et al. 2008 ; McIntyre et al.
2005). Patients treated with quetiapine (n=208) had
a similar chance of response (1.52, 95% CI 0.97–2.37,
I2=68%) and remission (1.59, 95% CI 0.86–2.94, I2=
73%), but a lower risk of discontinuation due to lack of
eﬃcacy than patients treated with placebo (n=197)
during the ﬁrst 3 wk of treatment. However, the NNT
was six (95% CI 3–9) and seven (95% CI 3–11) for
response and remission vs. placebo, respectively.
When data for the 12-wk studies were included,
patients treated with quetiapine had a higher chance
of response and remission vs. placebo. Diﬀerences
between 3 and 12 wk may be due to the dose titration
design in RCTs with quetiapine where the therapeutic
dose is reached several days after the ﬁrst study visit.
In comparison with other MDRs (n=299), patients
treated with quetiapine (n=310) had a similar chance
of response (I2=69%) and remission (I2=69%).
Risperidone. Data from three RCTs available in four
publications were included (Gopal et al. 2005 ;
Hirschfeld et al. 2004 ; Khanna et al. 2005 ; Smulevich
et al. 2005). Patients treated with risperidone (n=425)
had a 1.77 (95% CI 1.44–2.17, I2=33%) higher chance
of response, a 2.43 (95% CI 1.47–400) higher chance
of remission (I2=63%), and a lower risk of dis-
continuation due to lack of eﬃcacy in comparison
with patients treated with placebo (n=418). In com-
parison with other MDRs (n=309), patients treated
with risperidone (n=318) had a similar chance of
response and remission, and a similar risk of discon-
tinuation due to AEs, but a higher risk of discontinu-
ation due to any cause.
Ziprasidone. Three RCTs were included (Keck et al.
2003b ; Potkin et al. 2005; Vieta et al. 2008). Patients
treated with ziprasidone (n=446) had a 1.58 (95% CI
1.25–2.00, I2=0%) higher chance of response and a
lower risk of discontinuation due to lack of eﬃcacy
or any cause, but a greater risk of discontinuation due
to AE than those patients treated with placebo (n=
219). Six patients treated with ziprasidone instead of
placebo are needed to observe an additional AE. Data
from one RCT indicates that patients treated with
haloperidol (n=171) had a 1.48 (95% CI 1.17–1.87)
higher chance of response and a 1.43 (95% CI
1.01–2.03) higher chance of remission than patients
treated with ziprasidone (n=178), but a 2.53 (95% CI
1.08–5.94) higher risk of discontinuation due to AEs.
MDRs for acute depressive episodes
Many mood stabilizers (Ballenger & Post, 1980 ; Baron
et al. 1975 ; Davis et al. 2005 ; Donnelly et al. 1978 ; Fieve
et al. 1968 ; Geddes et al. 2009 (Trial SCAA2010) ;
Ghaemi et al. 2007 ; Goodwin et al. 1969, 1972 ; Mendels,
1976 ; Noyes et al. 1974 ; Post et al. 1986 ; Stokes et al.
1971), antidepressants (Baumhackl et al. 1989 ; Cohn
et al. 1989 ; Grossman et al. 1999 ; Himmelhoch et al.
1991 ; Silverstone et al. 2001 ; Thase et al. 1992), anti-
psychotics (DelBello et al. 2009) or other medications
(Smeraldi et al. 1999) have been evaluated as mono-
therapies in bipolar depression. Not one of those RCTs
fulﬁlled our study criteria therefore they were all ex-
cluded from the present analyses.
Nine RCTs fulﬁlling the study criteria on bipolar
depression were included (Table 2). The overall RR
for meta-analysis for response in bipolar depressed
patients treated with MDR (n=1419) compared with
placebo (n=1214) was 1.26 (95% CI 1.11–1.44, I2=
54%) (Fig. 3). Further, patients treated with MDR had
a 0.51 (95% CI 0.36–0.73, I2=46%) lower risk of dis-
continuation due to lack of eﬃcacy, but a 1.77 (95% CI
1.38–2.26, I2=0%) greater risk of discontinuation due
to AEs than those patients treated with placebo. We
did not observe a signiﬁcant diﬀerence vs. placebo for
the RR for remission, nor for discontinuation due to
any cause. Again, analyses including those trials with
small sample sizes (n=3) did not signiﬁcantly change
the ﬁnal results but increased their heterogeneity.
The included studies were all sponsored by the phar-
maceutical industry. They were heterogeneous with
respect to inclusion of subjects with history of a rapid-
cycling course or manic/mixed states, proportion of
people with/without psychotic symptoms, severity of
depression, rates of study completion, and proportion
of mood stabilizer-naive or antidepressant-naive sub-
jects.
Considering each MDR separately, we did not ﬁnd
any trials fulﬁlling our inclusion criteria to conﬁrm or
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reject any potential role for valproate as monotherapy
in acute bipolar depression, although a small RCT
suggests better remission rates for valproate vs. pla-
cebo (Davis et al. 2005). For other MDRs we found (Fig.
3 ; Tables 1 and 2) the following:
Lamotrigine. Data from three RCTs available in ﬁve
publications/data sources were considered for
analysis (Calabrese et al. 1999, 2008 ; Geddes et al.
2009 ; Trials SCA40910, SCA30924). We found that
patients treated with lamotrigine (o200 mg/d) (n=
327) had a similar chance of response (I2=0%) and
remission (one study), and a similar risk of
discontinuation due to lack of eﬃcacy or AEs than
those patients treated with placebo (n=317). Similar
results were observed when we included the BP I
and BP II patients, and all the doses evaluated for
lamotrigine.
Aripiprazole. Data from two RCTs available in three
publications/data sources were included (Thase et al.
2008 ; Trials CN138-096, CN138-146). Patients treated
with aripiprazole (n=373) had a similar chance of
response (I2=0%) and remission (I2=0%), but greater
risk of discontinuation due to lack of eﬃcacy or any
cause than those patients treated with placebo
(n=376).
Olanzapine. Data from two RCTs available in three
publications/data sources were included (Tohen et al.
2003b ; Trial 3077a). Patients treated with olanzapine
(n=350) had a 1.34 (95% CI 1.02–1.76, I2=51%) higher
chance of response, and a 1.24 (95% CI 1.05–1.46,
I2=0%) higher chance of remission, and a lower risk of
discontinuation due to lack of eﬃcacy, but a greater
risk of discontinuation due to AEs than those patients
treated with placebo (n=356).
Quetiapine. Data from two RCTs available in four
publications/data sources were included (Calabrese
et al. 2005; MacFadden et al. 2005 ; Thase et al. 2006 ;
Weisler et al. 2008). Patients treated with quetiapine
(n=435) had a 1.58 (95% CI 1.10–2.26, I2=74%) higher
chance of response, a 1.73 (95% CI 1.40–2.14)
(combined data) higher chance of remission, and a
lower risk of discontinuation due lack of eﬃcacy, but a
greater risk of discontinuation due to AEs than those
patients treated with placebo (n=222). Similar results
were observed when we evaluated together the BP I
and BP II patients in terms of response, remission or
discontinuations due to lack of eﬃcacy or AE.
Discussion
We found in most studies that MDRS are eﬃcacious in
the treatment of acute manic episodes. In these studies
the entire range of conﬁdence intervals exceeds the
cut-oﬀ point below which the eﬀect size is deﬁned as
no diﬀerent to placebo (Fig. 2). We also found that it is
necessary to treat six (95% CI 5–7) or seven (95% CI
5–8) patients to observe a signiﬁcant diﬀerence in re-
sponse or remission rates, respectively, with MDR
Study or subgroup
(1st-named author)
MDR
Events Total
Placebo
Events Total
Weight
(%)
Risk ratio
M-H, random, 95% Cl 
Risk ratio
M-H, random, 95% Cl 
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours MDR
Lamotrigine 200 mg/d
   Calabrese, 1999  
   Calabrese, 2008 (SCA30924) 
   Calabrese, 2008 (SCA40910)
   Total (95% CI) I 2 = 0%
Aripiprazole
   Thase, 2008 (CN138-096)
   Thase, 2008 (CN 138-146)
   Total (95% CI) I 2 = 0%    
Olanzapine
   Tohen, 2003b (3077a)-S1
   Tohen, 2003b (3077a)-S2
   Total (95% Cl) I 2= 51%
Quetiapine 300/600 mg/d
   Weisler, 2008
   MacFadden, 2005
   Total (95% CI) I 2 = 74%
Total (95% CI)
Heterogeneity: τ 2 = 0.02; χ 2 = 17.32, d.f. = 8 (p = 0.03); I2 = 54%
Test for overall effect: Z = 3.37 (p = 0.0008)
32
56
55
143
63
131
133
327
24
48
47
119
65
128
124
317
22.0
39.5
38.5
100.0
80
83
163
186
187
373
73
83
156
188
188
376
46.4
58.6
100.0
65
72
137
169
181
284
56
52
108
149
150
299
49.5
50.5
100.0
121
145
266
205
230
435
49
37
86
110
112
222
52.2
47.8
100.0
709 1419 469 1214 100.0
1.38 (0.92–2.05)
1.14 (0.85–1.54)
1.09 (0.81–1.48)
1.17 (0.97–1.41)
1.11 (0.87–1.41)
1.01 (0.80–1.26)
1.05 (0.89–1.24)
1.16 (0.88–1.53)
1.54 (1.17–2.02)
1.34 (1.02–1.76)
1.33 (1.04–1.68)
1.91 (1.44–2.53)
1.58 (1.10–2.26)
1.26 (1.10–1.44)
Fig. 3. Random risk ratios and 95% conﬁdence intervals (CIs) for response rates with a monotherapy drug regimen (MDR) vs.
placebo in the treatment of depressive episodes Response is deﬁned as a reductiono50% in the baseline total score in the
primary eﬃcacy measure after 7–10 wk of treatment. M-H, Mantel–Haenszel.
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over placebo in the treatment of acute manic episodes
(Table 2). Finally, a combined analysis with several
RCTS suggests that topiramate is not eﬃcacious in
the treatment of acute mania (Kushner et al. 2006). In
patients with acute manic episodes, study discontinu-
ation due to AEs was signiﬁcantly more likely to be
observed with a MDR than with placebo, but study
discontinuation due to lack of eﬃcacy or discontinu-
ation to any cause were signiﬁcantly lower with SGAS
than with placebo. Regarding the comparisons be-
tween an active compound against another MDR
(usually lithium, valproate or haloperidol), we did not
ﬁnd signiﬁcant diﬀerences in terms of response, re-
mission, or discontinuation due to AEs, lack of eﬃ-
cacy, or discontinuation due to any cause.
Regarding acute bipolar depressive episodes, we
found that only olanzapine and quetiapine showed
response and/or remission rates superior to those re-
ported with placebo (substantial heterogeneity was
observed with both analyses), although the eﬀect size
for quetiapine in response was almost double that for
olanzapine (Fig. 3). Early RCTs have shown signiﬁcant
therapeutic eﬀects with lithium for bipolar depression
(Thase & Sachs, 2000), but small samples and other
methodological shortcomings limits the evidence for
its use as a MDR for BP I depressed patients.
Although some patients with a bipolar depressive
episode may certainly beneﬁt from a MDR, the evi-
dence is still limited and many BP I patients with a
depressive episode appear to require the addition of
another mood stabilizer (Kramlinger & Post, 1989) or
an antidepressant (Tamayo et al. 2009 ; Tohen et al.
2003b ; Young et al. 2000). Interestingly, some RCTs
comparing a CDRwith aMDRwith no previous lack of
response did not report statistical diﬀerences favour-
ing the CDR in BP I-depressed patients (Amsterdam &
Shults, 2005 ; Brown et al. 2006 ; Nolen & Bloemkolk,
2000). On the other hand, although the literature sup-
ports the eﬃcacy of lamotrigine in preventing bipolar
depressive relapses (Goodwin et al. 2004), it does not
provide evidence to support the eﬃcacy of this medi-
cation in the acute depressive phase of BP I patients.
Recently, a review concluded that lamotrigine mono-
therapy did not demonstrate eﬃcacy in the acute
treatment of bipolar depression in four out of ﬁve
RCTs (Calabrese et al. 2008). However, a meta-analysis
with the same RCT, reported a statistically signiﬁcant
small eﬀect size of depressive symptom beneﬁt only in
patients with a HAMD score>24 (Geddes et al. 2009).
The relevance of diﬀerent therapeutic interventions
for BP I and their eﬃcacy must be evaluated based
on the best available evidence. Unfortunately, the
treatment of patients with BP I is usually complex, and
many treatment interventions implemented by clin-
icians at times may not be evidence-based. A survey in
an acute general psychiatric ward indicated that
<65% of treatment decisions were based on evidence
from RCTs (Goldner et al. 2001). Studies in which
pharmacological treatment is allocated by any method
other than randomization tend to show larger (and
frequently false-positive) treatment eﬀects than do
RCTs. Randomization prevents biased assignment of
treatment and confounders that are unknown or un-
measured (Chalmers et al. 1983). However, caution is
needed in drawing clear-cut generalizations to clinical
practice based on our analyses due to the heterogen-
eity in trial designs, the methodological quality of in-
cluded trials, and the nature, timing, and dose of
mood stabilizers or SGAs. Additionally, the fact that
almost all the RCTs in the ﬁeld of bipolar disorder are
aimed at registration approval, there may be a gap
between the evidence base of patients who participate
in clinical trials and clinical populations (Vieta &
Carne´, 2005).
We examined the results from available studies to
determine the possibility of publication bias or selec-
tive reporting bias. We additionally, compared the
data published with that reported on the trial registry
or at ‘ClinicalStudyResults.org’, and we excluded
trials with small sample sizes that would tend to show
larger estimates of the eﬀects of the intervention.
However, the quality of the studies varied and we
were not blinded to their quality when determining
their inclusion. Several analyses showed a heterogen-
eity statistic I2>50% that ‘may represent substantial
heterogeneity’ (Deeks et al. 2008) and the funnel plot
for each of them showed evidence of considerable
asymmetry. As noted by Higgins et al. (2003), regard-
ing heterogeneity, ‘ inconsistency of studies’ results
in a meta-analysis with reduced conﬁdence of rec-
ommendations about treatment’. Additionally, al-
though we examined the ‘ClinicalStudyResults.org’
webpage and several conference proceedings using
a combination of hand and electronic searching, we
cannot exclude the possibility that there are unpub-
lished negative studies that we were unable to access.
In conclusion, although there are patients who are
unresponsive to acute treatment with monotherapy,
these results suggest that MDRs should be considered
as a ﬁrst therapeutic option for the treatment of non-
refractory manic episodes. This approach may result
in the reduction of direct costs of medications, the
number and magnitude of AEs and may improve
treatment adherence and patient compliance (Grunze
et al. 2009). For depressive episodes, the new data with
SGAs (quetiapine and olanzapine) suggest that these
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MDR, especially quetiapine, are eﬃcacious and well
tolerated.
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